These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 3133217)

  • 1. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.
    Vlasveld LT; Beynen JH; Boogerd W; Ten Bokkel Huinink WW; Rodenhuis S
    Cancer Chemother Pharmacol; 1990; 25(5):382-3. PubMed ID: 2407368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission at laparotomy: still a gold standard in ovarian cancer?
    Neijt JP; ten Bokkel Huinink WW; Van der Burg ME; van Oosterom AT
    Lancet; 1986 May; 1(8488):1028. PubMed ID: 2871299
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Pinedo HM
    Radiother Oncol; 1984 Jun; 2(1):19-29. PubMed ID: 6438704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cytoreduction in ovarian cancer.
    Zanaboni F; Heintz AP; Trimbos JB; van Lindert AC; Aalders JG; Neijt JP
    Eur J Gynaecol Oncol; 1988; 9(2):149-52. PubMed ID: 3133212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of chemotherapy for ovarian carcinoma.
    ten Bokkel Huinink WW
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):583-5. PubMed ID: 3133217
    [No Abstract]   [Full Text] [Related]  

  • 8. Altretamine.
    Hansen LA; Hughes TE
    DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hexamethylmelamine in the management of ovarian cancer.
    Schein PS; Scheffler B; McCulloch W
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():67-75. PubMed ID: 1904311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy in the management of ovarian carcinoma: a review.
    Malpas JS
    J R Soc Med; 1979 May; 72(5):357-61. PubMed ID: 121890
    [No Abstract]   [Full Text] [Related]  

  • 11. Hexamethylmelamine (altretamine): early National Cancer Institute trials.
    Young RC
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():31-5. PubMed ID: 1904307
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy of ovarian cancer.
    Ozols RF; Young RC
    Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.